검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibition Therapy |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Male Breast Cancer; Stage II Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor |
MoA Biomarker | biomarkers, nutraceutical intervention for elevated prostate-specific antigen |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.. Estrogen is critical in the progression and probably also in the initiation of breast tumors. Two classes of pharmacologic agents currently used in the treatment of estrogen receptor-positive breast tumors are the selective estrogen receptor modulators such as tamoxifen that block the interaction of es… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT01823835 |
Clinical Data Tier / Score | A · 59 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibition Therapy |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Male Breast Cancer; Stage II Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor |
MoA Biomarker | biomarkers, nutraceutical intervention for elevated prostate-specific antigen |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.. Estrogen is critical in the progression and probably also in the initiation of breast tumors. Two classes of pharmacologic agents currently used in the treatment of estrogen receptor-positive breast tumors are the selective estrogen receptor modulators such as tamoxifen that block the interaction of es… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT01823835 |
Clinical Data Tier / Score | A · 59 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교